Article Per Year (5 Year)
p-Index From 2021 - 2026
1.978
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Farmasi dan Farmasi Klinik (Journal of Pharmaceutical Science and Clinical Pharmacy) Molecular and Cellular Biomedical Sciences (MCBS) Jurnal Mandala Pharmacon Indonesia International Journal of Applied Technology Research Tri Dharma Mandiri: Diseminasi dan Hilirisasi Riset Kepada Masyarakat (Jurnal Pengabdian Kepada Masyarakat) TRILOGI: Jurnal Ilmu Teknologi, Kesehatan, dan Humaniora International Journal of Economics (IJEC) Sciences of Pharmacy Jurnal Farmasi Kryonaut Riwayat: Educational Journal of History and Humanities Jurnal Informatika: Jurnal Pengembangan IT Folia Medica Indonesiana
Yulistiani Yulistiani, Yulistiani
Mahasiswa Jurusan Perencanaan Wilayah dan Kota, Fakultas Teknik, Universitas Diponegoro
Aerospace Engineering Humanities Automotive Engineering Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Control & Systems Engineering Dentistry Economics, Econometrics & Finance Education Electrical & Electronics Engineering Energy Engineering Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Materials Science & Nanotechnology Mechanical Engineering Medicine & Pharmacology Neuroscience Physics Public Health Social Sciences Other

Published : 28 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 28 Documents
Search

 1   2   3 
Analysis of Methyldopa Therapy on sFlt-1 Antiangiogenic Levels in Patients with Severe Preeclampsia Herwati, Teri Wina; Yulistiani, Yulistiani; M, Eddy Zarkaty
Folia Medica Indonesiana Vol. 54, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Methyldopa is the first-line drugs to treat hypertension in pregnancy. It can decrease blood pressure in preeclampsia by affecting a2-adrenoreceptors in central nervous system. However, it could also act by decreasing production of sFlt-1 antiangiogenic protein levels involved in the pathophysiology of hypertention in preeclampsia. The purpose of this study was to analyze methyldopa therapy on sFlt-1 antiangiogenic levels in the plasma of pregnant women with severe preeclampsia at the Obstetric Departement, Haji Hospital, Surabaya. This was a prospective study with observational cross-section study design. The sFlt-1 angiogenic levels were observed before and after (48 hours) methyldopa administration in severe preeclampsia patient with or without complications in the period of August to October 2016. Patient received methyldopa 250 mg or 500 mg, three times a day for clinical indications according a standard protocol. The study was approved by the ethical committee of Haji Hospital, Surabaya. There were 19 patients with preeclampsia who met the inclusion criteria, showed a decrease in the levels of sFlt-1 before and 48 hours after methyldopa therapy. Levels of sFlt-1 before methyldopa therapy in a dose of 250 mg was 10.15±10.00 (2.55-34.70) ng/ml and after therapy 8,37±9,20 (0.72-9.20) ng/ml, with a percentage decrease 17.54%. sFlt-1 levels before methyldopa therapy in a dose of 500 mg was 8.05±7.07 (2.55-20.76) ng/ml, after therapy 4.50±2.90 (2.19-9.95) ng/ml, with a percentage decrease 44.16%. Methyldopa therapy could decrease sFlt-1 levels of antiangiogenic factor in patients with severe preeclampsia.
Methotrexate use is safe in children with acute lymphoblastic leukemia Utomo, Febriansyah Nur; Yulistiani, Yulistiani; Zairina, Nun; Permono, Bambang
Folia Medica Indonesiana Vol. 53, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Monitoring level of methotrexate is not only aimed at monitoring effectiveness, but also safety aspects of the administration of high-dose methotrexate because the use of high-dose methotrexate is one of the problems associated with toxicity in various organs. In the use of high-dose methotrexate, measurement of methotrexate is important to identify patients with a high risk of toxicity, particularly nephrotoxicity as well as for dosing guidelines for leucovorin therapy. The aim of this study was to analyze the safety of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. This was a longitudinal, observational prospective study conducted to determine the safety profile of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. Patients who met the inclusion criteria were given high-dose methotrexate according to the 2013 Indonesian ALL Chemotherapy Protocol. Measurement of methotrexate level and kidney function was done 3 times on each cycle of chemotherapy consolidation phase. Measurements were made on the 0, 24 and 48 hours after the first drop of high-dose methotrexate. This study had been reviewed by Ethics Committee of Dr. Soetomo Hospital Surabaya. There were 12 patients who met inclusion criteria and 6 patients among them had finished their chemotherapy consolidation phase completely. There was no significant change in kidney function after the administration of high-dose methotrexate compared to baseline (p>0.05) and there was no significant correlation between serum level of methotrexate versus creatinine clearance. In conclusion, methotrexate was safe to use in children with acute lymphoblastic leukemia.
Analysis of High Dose and Long-Term Prednisone Therapy on Trap 5B Level Change in Children with Steroid Sensitive Nephrotic Syndrome Setyani, Dessy Surya; Qibtiyah, Mariyatul; Asmaningsih, Ninik; Yulistiani, Yulistiani
Folia Medica Indonesiana Vol. 54, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Nephrotic syndrome is a condition which is characterized by protein leakage from the blood to the urine through glomeruli. It leads to hypoproteinemia and generalised oedema. Patients with nephrotic syndrome need high dose and long term glucocorticoid such as prednisone. High dose and long term glucocorticoid can increase bone resorption. Biological marker is a valuable tool to evaluate efficacy of therapy. TRAP 5B is a sensitive biological marker for bone resorption because it reflects the number of osteoclasts. TRAP 5B is not affected by renal dysfunction and food. It also has a low diurnal variation than other bone resorption marker. The aim of this study was to analyze the changes of TRAP 5B levels at induction and alternate phase in children with steroid sensitive nephrotic syndrome. This observational prospective study was conducted from May to October 2016. Venous blood samples obtained at 08.00-10.00 am. TRAP5B levels were measured before and after induction phase and after alternate phase using ELISA. Fifteen patients were included in this study (60% boys). Majority of their age was 6 - <12 years and 40% were dependent steroid NS. TRAP 5B serum levels in induction phase increased by 37.41%±56.22%. In alternate phase, TRAP 5B serum levels increased by 28.75%±66.55% compared to the induction phase. However, the level change of both phases were not significant. As a conclusion, TRAP 5B levels increased in induction and alternate phase after high dose and long-term prednisone treatment in nephrotic syndrome.
Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia Widya, Reta Anggraeni; Nugroho, Susanto; Winarsih, Sri; Yulistiani, Yulistiani
Folia Medica Indonesiana Vol. 55, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level's targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients' ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.
Review : Alirocumab dan Evolocumab sebagai Agen Penurun Lipid Baru Alfatihah, Humaira Izka; Yulistiani, Yulistiani
Jurnal Mandala Pharmacon Indonesia Vol. 11 No. 2 (2025): Jurnal Mandala Pharmacon Indonesia 
Publisher : Program Studi Farmasi Universitas Mandala Waluya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35311/jmpi.v11i2.849

Abstract

Angka kematian yang disebabkan oleh penyakit kardiovaskular di seluruh dunia masih relatif tinggi. Salah satu faktor risikonya adalah LDL-C (low density lipoprotein cholesterol), di mana memodifikasi faktor ini diharapkan dapat mencegah kejadian kardiovaskular. Penghambat PCSK9 (proprotein convertase subtilisin/kexin type 9) adalah agen penurun lipid baru dengan mekanisme yang mempertahankan reseptor LDL-C di dalam darah. Untuk meninjau penelitian terbaru mengenai efektivitas dan keamanan agen penghambat PCSK9, Alirocumab dan Evolocumab, serta potensinya dalam menurunkan kadar lipid. Pencarian literatur menggunakan database elektronik PubMed dengan kata kunci ‘Alirocumab’, ‘Evolocumab’, ‘LDL-C’, ‘Kardiovaskular’, ‘Dislipidemia’, dengan kriteria 5 tahun terakhir dan teks lengkap dalam bahasa Inggris. Dari 12 artikel yang telah disaring kemudian akan direview. Nilai LDL-C menurun secara signifikan rata-rata 53% (11%-72%) dengan efek samping yang ringan, seperti nasofaringitis, diare, dan reaksi tempat suntikan. Alirocumab dan Evolocumab disuntikkan secara subkutan setiap 2 minggu atau 4 minggu. Penghambat PCSK9 berbasis antibodi monoklonal dapat menjadi alternatif untuk pencegahan kardiovaskular berisiko tinggi bagi pasien yang memiliki riwayat dosis statin yang dapat ditoleransi atau pasien yang tidak toleran terhadap statin.
Peran Pendamping Sosial terhadap Kualitas Hidup Pasien Lanjut Usia di Panti Sosial Tresna Werdha Budi Sejahtera I Yulistiani, Yulistiani
TRI DHARMA MANDIRI: Dissemination and Downstreaming of Research to the Community (Journal of Community Engagement) Vol 6 No 1 (2026)
Publisher : SMONAGENES Research Center, Univeritas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jtridharma.2026.006.01.22

Abstract

Pertambahan usia menyebabkan perubahan biologis dan psikososial yang dapat meningkatkan kerentanan lansia terhadap berbagai masalah kesehatan. Kondisi tersebut berpotensi memengaruhi kesejahteraan dan kualitas hidup mereka. Di Indonesia, proporsi penduduk lanjut usia terus menunjukkan tren peningkatan dan mencapai 11,75% pada tahun 2022. Berbagai faktor, baik fisik, emosional, maupun sosial, berkontribusi terhadap perubahan kualitas hidup pada kelompok usia ini. Penelitian ini bertujuan untuk mendeskripsikan kualitas hidup lansia dan mengkaji secara deskriptif peran pendamping sosial dalam meningkatkan kualitas hidup lansia di Panti Sosial Tresna Werdha Budi Sejahtera I, Kalimantan Selatan. Studi dilakukan menggunakan pendekatan observasional potong lintang terhadap 46 responden yang memenuhi kriteria penelitian. Pengukuran kualitas hidup dilakukan dengan instrumen World Health Organization Quality of Life-OLD. Hasil penelitian menunjukkan rata-rata skor kualitas hidup lansia sebesar 63,6% (kualitas hidup sedang), dengan domain aktivitas masa lalu, sekarang, masa depan serta domain persahabatan dan cinta kasih memperoleh skor tertinggi (67%), sementara domain kematian tercatat sebagai domain dengan skor terendah (50,7%). Temuan ini mengindikasikan bahwa dukungan sosial dan emosional yang diberikan pendamping sosial diduga berkontribusi dalam mempertahankan kualitas hidup lansia di lingkungan panti. Oleh karena itu, penguatan program pendampingan berbasis pendamping sosial menjadi strategi penting untuk menunjang kesejahteraan lansia di institusi sosial.
Genetic Polymorphism of N-acetyltransferase 2 (NAT2) among Patients with Tuberculosis: A Scoping Review of the Indonesian Studies Putra, Oki Nugraha; Ramadhani, Sylvia Rizki; Yulistiani, Yulistiani; Julaeha, Julaeha; Hidayatullah, Affan Yuniar Nur
Sciences of Pharmacy Volume 5 Issue 2
Publisher : ETFLIN

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0501599

Abstract

The distribution of N-acetyltransferase-2 (NAT2) genetic polymorphisms varies across ethnic groups among Indonesian TB patients. This review aimed to provide a comprehensive understanding of the prevalence of NAT2 genetic polymorphisms and their association with DILI and isoniazid pharmacokinetics in Indonesian TB patients. A scoping review was conducted by searching Google Scholar, Scopus, and PubMed in accordance with PRISMA guidelines for scoping review (PRISMA-ScR). We retrieved 668 studies from three databases and we enrolled 12 studies for final analysis. Eleven studies reported on adult TB patients and one study on pediatric TB patients. Overall, the available evidence suggests that the slow acetylator phenotype is relatively common among TB patients in Indonesia, although its distribution varies across regions and ethnic groups. The NAT2*6 polymorphism was frequently observed among TB patients with a slow acetylator phenotype. TB patients with slow acetylation exhibited higher serum concentrations of isoniazid, which were significantly associated with an increased risk of DILI. No studies reported an association between NAT2 genetic polymorphisms or acetylation status and treatment outcomes among TB patients. This review confirms substantial variation in NAT2 genetic polymorphisms across studies in Indonesia. TB patients with a slow acetylator phenotype appear to have a greater risk of developing DILI compared with those with intermediate or fast acetylator phenotypes. Information on acetylator status may identify patients at higher risk of hepatotoxicity, particularly those with the slow acetylator phenotype. Therefore, integrating NAT2 pharmacogenetics into clinical practice may predict hepatotoxicity and optimize tuberculosis therapy.
COST CONTROL OF PROTON PUMP INHIBITOR UTILIZATION AMONG NATIONAL HEALTH INSURANCE INPATIENTS AT TERTIARY HOSPITAL IN SURABAYA Umahati, Faradisa; Yulistiani, Yulistiani; Hamidi, Nur Fauzi; Sutrisno, Linda; Dianrana Dewi, Desak Made Rendang
Jurnal Farmasi Kryonaut Vol 5 No 2 (2026): JFK
Publisher : LPPM STIKES BULELENG

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59969/jfk.v5i2.204

Abstract

Proton pump inhibitors (PPIs) are widely used for the management of acid-related gastrointestinal disorders. Although their clinical efficacy is generally comparable, differences in acid-suppressive potency, duration of action, and acquisition costs may influence prescribing patterns and healthcare expenditures. This study aims to evaluate PPI utilization patterns and costs among hospitalized patients at a tertiary hospital in Surabaya, Indonesia, during 2023–2024 and to identify potential cost-control measures. This retrospective descriptive study analyzed PPI utilization data from the hospital information system for 2023–2024 and pharmacy billing records of National Health Insurance (JKN) patients from October to December 2024. Four oral and five injectable PPI formulations were utilized during the study period. Generic omeprazole, in both oral and injectable forms, accounted for the largest proportion of PPI use. Although injectable lansoprazole was prescribed less frequently, it contributed substantially to overall PPI expenditures. Omeprazole, lansoprazole, and pantoprazole were the most commonly prescribed PPIs among JKN patients. Pantoprazole, despite not being included in the hospital formulary, continued to be used and showed an increasing utilization trend. A shift in prescribing patterns from omeprazole to lansoprazole and pantoprazole in December 2024 was associated with increased costs. Omeprazole represented the highest utilization volume, whereas lansoprazole accounted for the largest share of PPI-related expenditures. Cost-control strategies should focus on optimizing formulary compliance and ensuring the appropriate use of higher-cost PPIs. Further studies evaluating clinical outcomes and the impact of formulary restrictions on lansoprazole use are warranted.
Co-Authors A.A. Ketut Agung Cahyawan W Agus Sulistyono Alfatihah, Humaira Izka Amarullah, Adinugraha Anggraini, Dian Septi Asmaningsih, Ninik Assaidiqi, M. Irfan Bagus PP Suryana, Bagus PP Bambang Permono Berliana, Dini Budi Suprapti Darto Saharso Desantika Wuryana, Desantika Dianrana Dewi, Desak Made Rendang Didik Hasmono Dwiyatna, Surya Ekanita Desiani Erwin Saputra Siregar Gustaji, F Hamidi, Nur Fauzi Herni Setyawati Herwati, Teri Wina Hidayatullah, Affan Yuniar Nur Julaeha, Julaeha Juwita, Dina Ratna Karisma, R F M, Eddy Zarkaty Mamo, Hendriette Irene Mariyatul Qibtiyah Markus, Unedo H Melawati Olevianingrum, Melawati Mellyani, Netty Purnama Sari Mia Ratwita Andarsini Muhammad Shohib, Muhammad Muhammad Yahya Muzayyanah, Binti Nazori, Nazori Nisriyati Fiddina Nun Zairina, Nun Nur ‘Azah Oktavia, Nur Permanasari, Ayu Ratna Purwiningtyas, Mida Putra, Oki Nugraha Rahmadani, Rizal Umar Ramadhani, Sylvia Rizki Rismayanti, Levana Rusmiyati, Melly Santi, Bayu Dharma Setyani, Dessy Surya Simbolon, Octaviana Soedarsono Soedarsono Sri Winarsih Styawati, Styawati Suharjono Susanto Nugroho Susilo, Dwi Hari Sutrisno, Linda Ugrasena, I DG Ugrasena, IGD Umahati, Faradisa UMI FATMAWATI Utomo, Febriansyah Nur WAHYU WIBISONO Widya, Reta Anggraeni Widya, Reta Anggraeni Wisudani, Nuraida